Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority

INTERLEUKIN 28B GENE POLYMORPHISMS AS A PREDICTOR OF TREATMENT RESPONSE IN EGYPTIANS WITH CHRONIC HEPATITIS C.

The effect of the polymorphism in IL-28B gene on the treatment response of a combined therapy by sofosbuvir and daclatasvir with and without ribavirin in HCV Egyptian patients

Interferon-ë rs12979860CC genotype predicts sustained virological response to therapy in patients with chronic hepatitis C Genotype 4 but enhances hepatic fibrosis

Interferon Lambda 4 Gene (IFNL4) Linked to Hepatitis C virus clearance, treatment

Role of interferon gamma gene polymorphism in spontaneous viral clearance versus chronicity in hepatitis C infected Egyptian patients

Interferon Therapy For Elderly Egyptian Patients With Chronic Hepatitis C of Genotype 4

Impact of gene polymorphism on Egyptian HCV patients under direct antiviral Drugs

Genetic study of I kappa B alpha gene promoter polymorphism associated with hepatitis C virus in Egyptian patients

The relation between interleukin 28B gene polymorphisms (rs8099917 and rs12980275) and the response of treatment of Hepatitis C Virus genotype 4 patients to Sofosbuvir and Daclat